Clearside Biomedical's Financial Efficiency Outshines Peers

• Clearside Biomedical, Inc. (NASDAQ:CLSD) boasts a Return on Invested Capital (ROIC) of 56.84% and a Weighted Average Cost of Capital (WACC) of 17.81%, indicating high capital efficiency.
• Its ROIC to WACC ratio of 3.19 significantly surpasses that of its competitors, highlighting Clearside's superior ability to generate profits over its cost of capital.
• Competitors like Cidara Therapeutics, Leap Therapeutics, and vTv Therapeutics show negative ROIC to WACC ratios, underscoring Clearside's standout performance in the biopharmaceutical industry.

Clearside Biomedical, Inc. (NASDAQ:CLSD) is a biopharmaceutical company focused on developing therapies to treat eye diseases. The company uses its proprietary SCS Microinjector to deliver drugs to the back of the eye, aiming to improve treatment outcomes. In the competitive landscape, Clearside stands out with its innovative approach, setting it apart from peers like Cidara Therapeutics, Leap Therapeutics, and others.

Clearside's Return on Invested Capital (ROIC) is an impressive 56.84%, while its Weighted Average Cost of Capital (WACC) is 17.81%. This results in a ROIC to WACC ratio of 3.19, indicating that the company is generating returns well above its cost of capital. This ratio is a key indicator of Clearside's efficiency in using its capital to generate profits.

In comparison, Cidara Therapeutics (CDTX) has a negative ROIC of -37.65% and a WACC of 8.75%, resulting in a ROIC to WACC ratio of -4.30. This negative ratio suggests that Cidara is not generating sufficient returns to cover its cost of capital, highlighting a less efficient use of its resources compared to Clearside.

Leap Therapeutics (LPTX) and vTv Therapeutics (VTVT) also show negative ROIC to WACC ratios of -26.76 and -21.29, respectively. These figures indicate that both companies are struggling to generate returns that meet or exceed their cost of capital, further emphasizing Clearside's superior performance in capital efficiency.

Selecta Biosciences (SELB) has a positive ROIC to WACC ratio of 0.92, the highest among its peers, yet still below 1. This suggests that while Selecta is closer to covering its cost of capital, it still falls short. In contrast, Clearside's strong ratio of 3.19 underscores its ability to generate substantial returns on its investments, setting a benchmark in the industry.